Ascentage Pharma Group International (AAPG) Long-Term Deferred Tax (2022 - 2025)

Ascentage Pharma Group International (AAPG) has reported Long-Term Deferred Tax for 4 consecutive years, with $4.5 million the latest figure, recorded in Q4 2025.

• Quarterly Long-Term Deferred Tax fell 26.84% year-over-year to $4.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.5 million (down 26.84% YoY) and the FY2025 annual result came in at $4.6 million, down 24.59% from the prior year.
• Long-Term Deferred Tax eased to $4.5 million in Q4 2025 per AAPG's latest filing, from $4.7 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for AAPG reached as high as $8.4 million in Q4 2022 and fell as low as $2.3 million in Q4 2023.
• A 4-year average of $5.2 million and a median of $4.7 million in 2025 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2023 — Long-Term Deferred Tax slumped 72.83% — and 2024, when it soared 170.34%.
• Year by year, Long-Term Deferred Tax stood at $8.4 million in 2022, then sank by 72.83% to $2.3 million in 2023, then soared by 170.34% to $6.2 million in 2024, then slipped by 26.84% to $4.5 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $4.5 million, $4.7 million, and $6.2 million for Q4 2025, Q2 2025, and Q4 2024 respectively.